Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Genesis Therapeutics
AddedFeb 13, 2024
UpdatedJun 13, 2026
Genesis Therapeutics

Genesis Therapeutics

Series B

Genesis Therapeutics uses AI to discover novel small-molecule medicines for challenging disease targets.

HQ
Palo Alto, CA, US
Founded
2019
Overview
Analysis
Compare
Fundraising
Employees
News
Website

Genesis Therapeutics is a clinical-stage biotechnology company applying advanced artificial intelligence and molecular simulation to discover and develop small-molecule therapies for difficult-to-drug disease targets. Its GEMS (Genesis Exploration of Molecular Space) platform integrates deep generative models, physics-based simulation, and large-scale computation to explore vast chemical space and predict molecular behavior with high fidelity.

The company has entered discovery collaborations with partners including Eli Lilly, Gilead Sciences, and Incyte, and is advancing wholly-owned and partnered programs across oncology and immunology. Founded in 2019 and headquartered in Burlingame, California, Genesis has raised more than $256 million in funding from investors such as Andreessen Horowitz, Radical Ventures, and T. Rowe Price.

Genesis Therapeutics - Products & Services

  • GEMS AI Platform logo

    GEMS AI Platform

    GEMS (Genesis Exploration of Molecular Space) is a generative AI platform for small-molecule drug discovery.

    Competing Products

    Origin Bio logo
    Insilico Medicine logo
    Recursion Pharmaceuticals logo

Genesis Therapeutics - Similar Companies

Origin Bio logo

Origin Bio

origin.bio

Recursion Pharmaceuticals logo

Recursion Pharmaceuticals

recursion.com

Insilico Medicine logo

Insilico Medicine

insilico.com

Genesis Therapeutics - Quick Facts

Who are Genesis Therapeutics' competitors?

Companies similar to Genesis Therapeutics include Origin Bio, Recursion Pharmaceuticals and Insilico Medicine.

When was Genesis Therapeutics founded?

Genesis Therapeutics was founded in 2019.

Where is Genesis Therapeutics' headquarters located?

Genesis Therapeutics' headquarters is located in Palo Alto, CA, US.

When was Genesis Therapeutics' last funding round?

Genesis Therapeutics' most recent funding round was for $200M (USD) in August 2023.

How much has Genesis Therapeutics raised to-date?

As of Aug 21, 2023, Genesis Therapeutics has raised a total of $256.1M (USD).

How many employees does Genesis Therapeutics have?

Genesis Therapeutics has 121 employees as of Jun 1, 2026.

Genesis Therapeutics - Classification

Industry
  • Biotechnology
Ownership
  • Venture Capital
Technology
  • AI
  • Machine Learning
Geographic Exposure
  • Global
Model
  • AI Platform
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Tags
  • AI Operations
  • Biotech
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541500Computer Systems Design and Related Services
  • 541000Professional, Scientific, and Technical Services
  • 541510Computer Systems Design and Related Services
  • 541511Custom Computer Programming Services
SIC
  • 7300Business Services
  • 7370Computer Programming, Data Processing, And Other Computer Related
  • 7371Computer Programming Services
Show 15 more industry codes
NAICS
  • 513200Software Publishers
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 510000Information
  • 620000Health Care and Social Assistance
  • 513000Publishing Industries
  • 541700Scientific Research and Development Services
  • 513210Software Publishers
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
  • 8000Health Services
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8730Research, Development, And Testing Services
  • 7372Prepackaged Software
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified
  • 8731Commercial Physical and Biological Research